We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Real-world use of omalizumab in patients with chronic idiopathic/spontaneous urticaria in the United States.
- Authors
Eghrari-Sabet, Jacqueline; Sher, Ellen; Kavati, Abhishek; Pilon, Dominic; Zhdanava, Maryia; Balp, Maria-Magdalena; Lefebvre, Patrick; Ortiz, Benjamin; Bernstein, Jonathan A.
- Abstract
BACKGROUND: Omalizumab was approved for the treatment of chronic idiopathic urticaria (CIU)/chronic spontaneous urticaria (CSU) in the United States in March 2014. OBJECTIVE: This study sought to describe real-world omalizumab use, in the United States, in a large cohort of patients with CIU/CSU. METHODS: Patients with CIU/CSU (ages ≥12 years) initiated on omalizumab (index date) with ≥12 months of pre- and postindex data were identified in the an insurance claims data base (January 1, 2013, to July 31, 2016). Treatment patterns, including the dosing regimen and continuous use of omalizumab (no gaps for ≥60 days), were described during the 12-month postindex follow-up period. RESULTS: A total of 1546 patients (mean ± standard deviation [SD] ages, 44 ± 14.5 years; 73.1% women) were identified. Most of the patients (84.5%) were initiated on omalizumab 300-mg dose; 90% maintained the initial dose, 7.5% had a dose increase, and 4.6% had a dose decrease. The mean ± SD omalizumab treatment duration was 9.1 ± 3.8 months, the mean ± SD number of omalizumab administrations was 8.3 ± 4.8, and the mean ± SD administration frequency was 44 ± 29 days. A proportion of the patients continuously treated with omalizumab for 6, 9, and 12 months was 67.3, 54.8, and 47.4%, respectively. Among the patients who discontinued omalizumab for ≥3 months (39.8%), 21% restarted the treatment after a mean ± SD of 4.4 ± 1.3 months. The proportion of patients who used other CIU/CSU-related medications decreased pre- to postindex (94.8 to 81.1%), with the highest decrease observed in oral corticosteroids (75.7 to 49.9%).
- Subjects
URTICARIA; MEDICATION safety; DRUG efficacy; HEALTH outcome assessment; HEALTH insurance
- Publication
Allergy & Asthma Proceedings, 2018, Vol 39, Issue 3, p191
- ISSN
1088-5412
- Publication type
Article
- DOI
10.2500/aap.2018.39.4132